Yifeng Pharmacy Chain (603939) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached ¥11.76 billion, up 9.86% year-over-year, driven by organic growth, new store openings, M&A, and franchise expansion.

• Net profit attributable to shareholders was ¥797.72 million, up 13.13% year-over-year; adjusted net profit (excluding non-recurring items) rose 15.77%.

• The company added 1,575 new stores (842 self-built, 293 acquired, 440 franchise), with a net increase of 1,486 stores, totaling 14,736 at period end.

• Proposed interim cash dividend of ¥0.25 per share (totaling ¥303.11 million), pending shareholder approval.

Financial highlights

• Operating cash flow was ¥1.82 billion, up 29.41% year-over-year.

• Total assets grew 9.53% to ¥26.44 billion; net assets attributable to shareholders rose 4.13% to ¥10.21 billion.

• Basic and diluted EPS were both ¥0.66, up 13.79% year-over-year.

• Gross margin and net margin improved, with cost increases mainly due to scale and new store integration.

• Non-recurring gains totaled ¥11.94 million, mainly from asset disposals and government grants.

Outlook and guidance

• Management expects continued growth via "new openings + M&A + franchise" and digital transformation.

• Focus remains on regional penetration, supply chain optimization, and digital operations to drive efficiency and profitability.

• Industry trends support further consolidation and expansion, with regulatory and pricing reforms ongoing.